Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Associated Therapies: -

Clinical Trials

Clopidogrel Resistance and Embolism in Carotid Artery Stenting

Phase 3

Conditions: Carotid Stenosis

Interventions: Drug: Ticlopidine + Ginko biloba
Drug: Clopidogrel

First Posted Date: 2014-05-08

Last Posted Date: 2017-04-26

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 86

Registration Number: NCT02133989

Locations: 🇰🇷
Oh Young Bang, Seoul, Korea, Republic of

Comparison of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function

Phase 4

Conditions: ST-Segment Elevation Myocardial Infarction

Interventions: Drug: Ticagrelor
Drug: Clopidogrel

First Posted Date: 2014-04-25

Last Posted Date: 2015-02-25

Lead Sponsor: Jinan Central Hospital

Target Recruit Count: 350

Registration Number: NCT02123004

Locations: 🇨🇳
Jinan Central Hospital, Jinan Shi, Shandong, China

Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients

Phase 4

Withdrawn

Conditions: Peripheral Artery Disease
Vascular Disease
Arterial Occlusion Disease
Intermittent Claudication
Ankle Brachial Index (0.9 or Less)

Interventions: Drug: Ticagrelor
Drug: clopidogrel

First Posted Date: 2014-04-23

Last Posted Date: 2014-10-15

Lead Sponsor: AstraZeneca

Registration Number: NCT02121288

The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man

Phase 2

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Ticagrelor
Drug: Clopidogrel
Drug: Placebo
Drug: ASA

First Posted Date: 2014-04-22

Last Posted Date: 2014-04-22

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 89

Registration Number: NCT02120092

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management

Phase 4

Completed

Conditions: Acute Coronary Syndrome
Cardiovascular Diseases
Myocardial Ischemia
Heart Diseases
Angina Pectoris

Interventions: Drug: Ticagrelor
Drug: Clopidogrel

First Posted Date: 2014-03-24

Last Posted Date: 2018-11-30

Lead Sponsor: Seung-Jung Park

Target Recruit Count: 800

Registration Number: NCT02094963

Locations: 🇰🇷
Dong-A Medical Center, Pusan, Korea, Republic of
🇰🇷
Ulsan University Hospital, Ulsan, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of

and more 7 locations